Disorders of iron metabolism. Part 2
Authors:
J. Novotný
Authors‘ workplace:
Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc., Transfuzní oddělení a krevní banka FN Brno, pracoviště Bohunice, přednosta prim. MUDr. Eva Tesařová
Published in:
Vnitř Lék 2005; 51(9): 995-1006
Category:
Reviews
Overview
Disorders of iron metabolism are very frequently seen in clinical medicine. Up to 60% of women in gestational age suffer from some degree of sideropenia. Sideropenia occurs in situations with the negative bilance of this vital element - i.e. in patients with chronic blood loss, in vegetarians or in malaabsorptive syndromes and in states with increasing utilization of iron in gravidity, lactation or in pubescents. The iron overload represents the opposite situation and is foundmainly in transfusion dependent patients, in some hemolytic states with inefective erythropoesis, in severe hepatopathias and in patients with congenitaly incerased absorption of iron - i.e. in hereditary hemochromatosis type I-V. The classical hereditary hemochromatosis (type I) was firstly described in the 19th century as so called „bronze diabetes“. It was the full penetrance of hereditary iron overload which affected the parenchymatous organs (mainly the liver), heart, joints, skin and endocrine glands. The main candidate gene was firstly described in 1966 by Feder et al. and was called HFE gene. HFE gene maps to the 6th chromosome close to the HLA locuses and reveals with the MHC (main histocompatibility complex) genes some homology. Mature HFE protein is associated with ß2microglobuline and localized in the cytoplasmatic membrane, where this complex associates with transferrin receptors. This interaction with the transferrin receptors modulates the endocytosis of transferrin iron; there is not consensus in the literature about sense of the modulation (potentiation or inhibition of transferrin iron endocytosis). More than 30 mutations and polymorphisms in the HFE gene were discovered; the most frequent are the point mutations C282Y, H63D, and S65C. The most frequent genetic basis of hereditary hemochromatosis in caucasoids is the C282Y mutation, prevalence of heterozygotes in the Caucasoid populations being from 5 to 12 percent. The C282Y mutation can be revealed in about 80% of Caucasoid patients with the diagnosis of hereditary hemochromatosis. The classic hereditary hemochromatosis represents the autosomal recessive trait with incomplete penetrance, which is estimatedin the broad interval from 1 to 50 percent. The mutations in other genes, which code for other proteins of iron metabolism, were revealed. This mutations cause so called „non-HFE hemochromatoses“. The clinical picture of these deseases may be other than the picture of classic hemochromatosis, some the non-HFE iron overloads may be inherited in the dominant manner. The most frequently disscussed topic today is the exact mechanism/s leading to iron overload in HFE and non-HFE hemochromatosis, the genetic screening for HFE mutations in general population at risk and the relation of iron overload to atherosclerosis, diabetes and malignant diseases. These and other problems are under intensive research in many centres and only the future will bring the answers to these important questions.
Key words:
iron - sideropenia - iron overload - hereditary hemochromatosis
Sources
1. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485-504.
2. American Society of Human Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995; 57: 1233-1241.
3. Annichino-Bizzacchi JM, Saad STO, Arruda VR et al. C282Y mutation in the HLA-H gene is not a risk factor for patients with myocardial infarction. J Cardiovasc Risk 2000; 7: 37-40.
4. Arden KE, Wallace DF, Dixon JL et al. A novel mutation in ferroportin 1 is associated with haemochromatosis in a Solomon Islands patient. Gut 2003; 52: 1215-1217.
5. Battiloro E, Ombres D, Pascale E et al. Haemochromatosis gene mutations and risk of coronary artery disease. Eur J Hum Genet 2000; 8: 389-392.
6. Beutler E, Felitti VJ, Koziol JA. Penetrance of 845 G-A (C282Y) HFE hereditary hemochromatosis in the USA. Lancet 2002; 359: 211-218.
7. Bozzini C, Girelli D, Tinazzi E et al. Biochemical and genetic markers of iron status and the risk of coronary artery disease: An angiography-based study. Clin Chem 2002; 48: 4.
8. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen 1996; 3: 178-184.
9. Burke W, Imperatore G, McDonell SM et al. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2000; 2: 271-277.
10. Calado RT, Franco RF, Pazin-Filho A et al. HFE gene mutations in coronary atherothrombotic disease. Brazil J Med Biol Res 2000; 33: 301-306.
11. Camaschella C, Roetto A, Cali A et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
12. Cazzola M. Genetic disorders of iron overload and the novel „ferroportin disease“. Haematologica 2003; 88: 721-724.
13. Claeys D, Walting M, Julmy F et al. Haemochromatosis mutations and ferritin in myocardial infarction: a case-control study. Eur J Clin Invest 2002; 32(Suppl 1): 3-8.
14. Coppin H, Bensaid M, Fruchon S et al. Longevity and carrying the C282Y nutation for haemochromatosis on the HFE gene: case control study of 492 French centenarians. Brit Med J 2003; 327: 132-133.
15. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996; 13: 399-408.
16. Fernandez-Real JM, Penarroja G, Castro A et al. Blood letting in high-ferritin type 2 diabetes. Effects on insulin sensitivity and β-cell function. Diabetes 2002; 51: 1000-1004.
17. Fleming RE, Ahmann JR, Migas MC et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci USA 2002; 99: 10653-10658.
18. Franco RF, Zago MA, Trip MD. Prevalence of hereditary hemochromatosis in premature atherosclerotic vascular disease. Brit J Haematol 1998; 102: 1172-1175.
19. Gehrke SG, Kulaksiz H, Herrmann T et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003; 102(1): 371-376.
20. Guillygomarc’h A, Mendler MH, Moirand R et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001; 35: 344-349.
21. Hann HWL, Stahlhut MW, Menduke H. Iron enhances tumor growth. Cancer 1991; 68: 2407-2410.
22. Hoffmann WK, Tong XJ, Ajioka RS et al. Mutation analysis of transferrin receptor 2 in patients with atypical hemochromatosis. Blood 2002; 100: 1099-1100.
23. Imperatore G, Pinsky LE, Motulsky A et al. Hereditary hemochromatosis: perspectives of public health, medical genetics, and primary care. Genetics in Medicine 2003; 5: 1-8.
24. Jensen PD. Evaluation of iron overload. Brit J Haematol 2004; 124: 697-711.
25. Jones DC, Young NT, Pigott C et al. Comprehensive hereditary hemochromatosis testing. Tissue Antigens 2002; 60: 481-488.
26. Kato J, Fujikawa K, Kanda M et al. A mutation in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69: 191-197.
27. Kawabata H, Yang R, Hirama T et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826-20832.
28. Klipstein-Grobusch K, Koster JF, Grobbee DE et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999; 69: 1231-1236.
29. Kraml P, Potočková J, Kopřivová H et al. Feritin, oxidační stres a koronární ateroskleróza. Vnitř Lék 2004; 50(3): 197-202.
30. Le Gac G, Mons F, Jacolot S et al. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Brit J Haematol 2004; 125: 674-678.
31. Lee PL, Halloran C, Trevino R et al. Human transferrin G277S mutation. A risk factor for iron deficiency anemia. Brit J Haematol 2001; 115: 329-333.
32. Lee PL, Beutler E, Rao SV et al. Genetic abnormalities and juvenile hemochromatosis: mutation of the HJV gene encoding hemojuvelin. Blood 2004; 103: 4669-4671.
33. Leitman SF, Browning NJ, Yau YY et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43: 1538-1544.
34. Magnusson MK, Sigfusson N, Sigvaldasson H et al. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89: 102-108.
35. Mattman A, Huntsman D, Lockitch G et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002; 100: 1075-1077.
36. Meyers DG. The iron hypothesis: does iron play a role in atherosclerosis? Transfusion 2000; 40: 1023-1029.
37. Montosi G, Paglia P, Garuti C et al. Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood 2000; 96: 125-1129.
38. Muckenthaler M, Roy CN, Custodio AO et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hermochromatosis. Nature Genetics 2003; 34: 102-107.
39. Muncunill J, Vaquer P, Galmés A et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apheresis 2002; 17: 88-92.
40. Nash S, Morconi S, Sikorska K et al. Role of liver biopsy in the diagnosis of hepatic iron overload in the era of genetic testing. Am J Clin Pathol 2002; 118: 73-81.
41. Neff LM. Current directions in hemochromatosis research: towards an understanding of the role of iron overload and the HFE gene mutations in the development of clinical disease. Nutrition Rev 2003; 61, 1: 38-42.
42. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci. USA 2001; 98: 8780-8785.
43. Nicolas G, Viatte L, Lou DQ et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nature Genetics 2003; 34: 97-101.
44. Olynyk J, Cullen D, Aquilia S et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
45. Racek J. Železo, volné radikály a ateroskleróza (Editorial). Vnitr Lek 2004; 50(3): 181-183.
46. Ramakrishnan U, Kuklina E, Stein AD. Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 2002; 76: 1256-1260.
47. Rivard SR, Lanzara C, Grimard D et al. Autosomal dominant reticuloendotelial iron overload due to a new missense mutation in the ferroportin 1 gene in a large French-Canadian family. Haematologica 2003; 88: 824-826.
48. Roetto A, Daraio F, Alberti F et al. Hemochromatosis due to mutations in transferring eceptor 2. Blood Cells, Molecules, and Diseases 2002; 29: 465-470.
49. Roetto A, Merryweather-Clarke AT, Daraio F et al. A valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4. Blood 2002; 100: 733-734.
50. Roetto A, Papanikolaou G, Politou M et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nature Genetics 2003; 33: 21-22.
51. Ruddy DA, Kronmal GS, Lee VK et al. A1.1-Mb transcript map of the hereditary hemochromatosis locus. Genome Res 1997; 7: 441-456.
52. Salvioni A, Mariani R, Oberkanis C et al. Prevalence of C282Y and E168X mutations in an Italian population of Nothern European ancestry. Haematologioca 2003; 88: 250-255.
53. Seth S, Brittenham GM. Genetic disorders affecting proteins of iron metabolism: Clinical implications. Annu Rev Med 2000; 51: 443-464.
54. Soška V. Má sérová koncentrace feritinu, protilátek proti oxidovaným LDL a vitaminů vztah k riziku koronární aterosklerózy? (Editorial) Vnitr Lek 2004; 50(3): 183-185.
55. Tuomainen TP, Kontula K, Nyyssönen K et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation. A prospective cohort study in men in Eastern Finland. Circulation 1999; 100: 1274-1279.
56. Waheed A, Grubb JH, Zhou XY et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 2002; 99: 3117-3122.
57. Wallace DF, Pederson P, Dixon JL et al. Novel mutation in ferroportin 1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692-694.
58. Whittington CA, Kowdley KV. Review article: haemochromatosis. Aliment Pharmacol Therapeut 2002; 16: 1963-1975.
59. Willis G, Wimperis JZ, Smith KC. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999; 354: 221-222.
60. Zacharski LR, Gerhard GS. Atherosclerosis: a manifestation of chronic iron toxicity? Vasc Med 2003; 8: 153-155.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
![Issue 9](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/856b2102c9e8cefefd8f81d0ace9b4da.jpeg)
2005 Issue 9
Most read in this issue
- Carcinoid
- Disorders of iron metabolism. Part 2
- Migraeflux in acute treatment of migraine
- Relevance of left ventricular contractile reserve evaluated by dobutamine echocardiography in patients with advanced chronic heart failure